APTO

Aptose Biosciences, Inc.

0.77 USD
+0.01 (+1.32%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aptose Biosciences, Inc. stock is down -28.7% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 9 June’s closed higher than May. 100% of analysts rate it a buy.

About Aptose Biosciences, Inc.

Aptose Biosciences discovers and develops personalized therapies addressing unmet medical needs in oncology. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and HR MDS. The company also develops luxeptinib, a dual bromodomain and extra-terminal domain motif motif motif protein and kinase inhibitor program.